Loading patent…
AssigneeXCYTE Therapies, Inc.
InventorsRonald Berenson, Che Law, Mark Bonyhadi, Narinder Saund, Stewart Craig, Alan Hardwick, Dale Kalamasz, David McMillen
Estimating the term…
The present invention relates generally to methods for stimulating cells, and more particularly, to a novel method to concentrate and stimulate cells that maximizes stimulation and/or proliferation of such cells. In the various embodiments, cells are stimulated and concentrated with a surface yielding enhanced proliferation, cell signal transduction, and/or cell surface moiety aggregation. In certain aspects methods for stimulating a population of cells such as T-cells, by simultaneous concentration and cell surface moiety ligation are provided by contacting the population of cells with a surface, that has attached thereto one or more agents that ligate a cell surface moiety and applying a force that predominantly drives cell concentration and cell surface moiety ligation, thereby inducing cell stimulation, cell surface moiety aggregation, and/or receptor signaling enhancement. Also provided are methods for producing phenotypically tailored cells, including T-cells for the use in diagnostics, drug discovery, and the treatment of a variety of indications, including cancer, viral infection, and immune related disorders. Compositions of cells having specific phenotypic properties produced by these processes are further provided.
A method for stimulating a population of T-cells by simultaneous T-cell concentration and cell surface moiety ligation, comprising:
A method for stimulation of T-cells by simultaneous cell surface moiety ligation and T-cell aggregation, comprising:
A method adapted for inducing T-cell activation in vivo, comprising providing paramagnetic particles to an animal, said particles having attached thereto, ligands specific for a T-cell surface moiety that induces T-cell activation;
A method for stimulating a population of target cells by simultaneous target cell concentration and target cell surface moiety ligation, comprising:
A method for stimulation of target cells by cell surface moiety ligation and target cell concentration, comprising:
A method of inducing target cell stimulation in vivo, comprising providing paramagnetic particles to an animal, said particles having attached thereto, ligands specific for a target cell surface moiety that induces target cell stimulation;
A method for inducing receptor polarization in receptor bearing cells, comprising:
A method for inducing aggregation of cell surface molecules, comprising:
A method for inducing a population of T-cells to proliferate, comprising contacting the T-cells with a solid surface for a period of time of between about two hours and about nine days, said solid surface having immobilized thereon a first agent and second agent, and wherein said first agent provides an activation signal and said second agent provides a co-stimulatory signal to said T-cells.
A population of T-cells produced by any one of methods 129-138.
A method for inducing a population of T-cells to proliferate, comprising:
A population of activated T-cells, wherein at least a subset of the cells have a phenotype in which CD154 levels peak between about one and about four days post-stimulation.
A population of activated T-cells, wherein said population comprises greater than about 60% CD4+ T-cells.
A population of activated T-cells, wherein said population comprises at least about 70% CD4+ T-cells.
A population of activated T-cells previously stimulated to proliferate by contact with anti-CD3 and anti-CD28 antibodies or fragments thereof for a period of about two hours to about nine days.
A population of activated T-cells wherein said T-cells have previously been induced to proliferate by contact with an immobilized first agent and second agent for a period of between about two hours and about nine days, wherein said first agent provides an activation signal and said second agent provides a co-stimulatory signal to said T-cells.
A method for depleting monocytes from a suspension comprising T-cells and monocytes, comprising contacting the suspension with para-magnetic beads, wherein said beads have a diameter of between about 2.8 μm and about 10 μm, and subsequently separating the monocytes from the suspension by magnetic attraction.
A population of stimulated T-cells having CD154 expression levels at least 10% higher than T-cells that have been stimulated with anti-CD3 and anti-CD28 antibodies in the absence of simultaneous concentration and stimulation, wherein said levels are determined by flow cytometry between days 1 to 4 following T-cell stimulation.
A population of stimulated T-cells having CD25 expression levels at least 10% higher than T-cells that have been stimulated with anti-CD3 and anti-CD28 antibodies in the absence of simultaneous concentration and stimulation, wherein said levels are determined by flow cytometry between days 1 to 4 following T-cell stimulation.
Dependencies are inferred from the claim text.